US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Nexalin Technology, Inc. - Warrant
(NQ:
NXLIW
)
0.0138
UNCHANGED
Last Price
Updated: 3:18 PM EDT, Sep 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nexalin Technology, Inc. - Warrant
< Previous
1
2
3
4
Next >
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
October 14, 2024
Veteran medical device executive to drive regulatory and clinical strategy as Nexalin advances drug-free Deep Intracranial Frequency Stimulation (DIFS) technology for mental health treatment
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
September 05, 2024
Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
July 18, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Closing of $5.2 Million Public Offering
July 01, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
June 27, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
June 20, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
June 13, 2024
Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders
From
Nexalin Technology, Inc.
Via
GlobeNewswire
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
June 06, 2024
Via
ACCESSWIRE
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
June 04, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
June 03, 2024
Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
May 22, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
May 09, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
April 25, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
April 09, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
April 04, 2024
New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
April 02, 2024
Previously served as Acting General Counsel to the Department of Veterans Affairs
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
March 28, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
March 14, 2024
Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
March 13, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
March 06, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
February 08, 2024
Company’s International Reach Expanding with Latest Regulatory Approval
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
January 23, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Unveils Next-Generation HALO™ Clarity
January 11, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
December 18, 2023
Results published in General Psychiatry, a leading peer-reviewed journal
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
October 25, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
October 16, 2023
Study reveals that Nexalin’s non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and...
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
August 07, 2023
New migraine data builds on prior clinical studies in depression
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
August 03, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
July 26, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
July 10, 2023
New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation with TBI
From
Nexalin Technology, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
